Gout

Etiology and Clinical Context

Gout reflects an imbalance between urate generation and renal or intestinal excretion. Underexcretion is common; chronic kidney disease, diuretic therapy, metabolic disease, genetics, and high urate exposure contribute to risk. Alcohol intake and dietary purine/fructose exposures may modify risk but should not be mistaken for the entire cause.

Urate solubility in physiologic fluids is approximately 6.8 mg/dL, although crystal formation also depends on temperature and local conditions. Cooler peripheral joints, especially the first metatarsophalangeal joint, are common sites. Many patients with hyperuricemia never develop gout.

Epidemiology and Risk Profile

Risk increases with age and is higher in men through much of adulthood, with the difference narrowing after menopause. Chronic kidney disease and medications that affect urate handling also change pretest probability. These factors help frame the history but cannot establish the cause of an acutely inflamed joint.

Pathophysiology

Initiation: crystals and innate immune activation

Monosodium urate crystals are recognized by innate immune cells and promote NLRP3 inflammasome activity, caspase-1 activation, and processing of pro-interleukin-1β. The resulting IL-1β-rich environment recruits neutrophils and stimulates additional mediators. This produces abrupt erythema, warmth, swelling, and extreme pain, commonly reaching maximal intensity within a day (Gelber et al., 2019).

Propagation and resolution

Neutrophils ingest crystals and release reactive mediators, amplifying synovitis. An acute attack can eventually self-resolve as anti-inflammatory feedback, altered crystal coating, and cellular clearance dampen the response. Resolution of pain does not mean that deposited crystals have disappeared.

Chronic tissue injury

Persistent urate burden forms tophi composed of crystal aggregates surrounded by inflammatory and fibrotic tissue. Recurrent inflammation and tophaceous deposition can erode bone and impair joint function. Urate-related nephrolithiasis and concurrent kidney disease influence risk and management, although hyperuricemia is not itself proof of gouty renal injury.

Why Gout Flares and Then Remits

A joint may become exquisitely painful overnight after years of relatively silent urate deposition. Once the inflammatory response subsides, residual crystals can still provoke another attack. This is why successful flare treatment does not eliminate the need to assess long-term urate burden.

Clinical observation	Underlying process	Implication
Podagra with abrupt nocturnal onset	Local urate crystals trigger intense innate immunity	Acute evaluation must also exclude infection
Negative or normal urate during a flare	Serum urate fluctuates and is not a crystal test	Do not rule out gout based on one result
Recurrent flares or tophi	Persisting crystal burden	Consider long-term urate lowering and prophylaxis
Immediate response to colchicine	Neutrophil microtubule inhibition reduces inflammation	The drug does not lower urate or eliminate crystals

Compare with SLE: gout’s acute inflammatory effector cascade may subside relatively quickly; lupus can repeatedly flare because adaptive immune recognition of self-antigens and autoantibody production persist. Both conditions can relapse, but their initiating triggers and long-term therapies differ.

Clinical Manifestations

Typical initial presentations involve sudden, severe monoarthritis, often affecting the first MTP joint, midfoot, ankle, or knee. Later episodes may be polyarticular. Skin can appear red and shiny; even minimal touch may be intolerable. Tophi may appear at the ear helix, olecranon bursa, fingers, or feet during longstanding uncontrolled disease.

Flare triggers can include illness, surgery, local trauma, changes in volume status, and rapid shifts in serum urate, including during initiation of urate-lowering therapy. A patient can have both chronic hyperuricemia and an independent reason for a hot joint.

Diagnostic Evaluation

Synovial aspiration with polarized microscopy demonstrating needle-shaped, negatively birefringent monosodium urate crystals establishes the diagnosis when available. Send cell count/differential and microbiologic studies when infection is possible. Inflammatory cell counts overlap with septic arthritis.

Serum urate is helpful for longer-term management, not a stand-alone acute diagnostic test. Ultrasound may show a double-contour sign or tophi; dual-energy CT can identify urate deposits when aspiration is not feasible. Evaluate kidney function, medication exposures, frequency of flares, and tophus burden.

Expected Findings and Diagnostic Interpretation

Test or observation	Supports	Limitation and clinical consequence
Synovial fluid crystal examination	Monosodium urate forms needle-shaped, strongly negatively birefringent crystals	Microscopy requires an adequate specimen and operator skill; also evaluate infection when indicated
Synovial leukocyte count	Can be markedly inflammatory during a gout flare	Septic arthritis and gout may overlap in cell count and neutrophil predominance
Gram stain and culture	Positive culture supports concomitant or alternative septic arthritis	A negative Gram stain is insensitive; final culture and clinical follow-up matter
Serum urate during a flare	Helps characterize urate burden only when interpreted longitudinally	Normal or reduced level does not exclude a gout flare; repeat after acute illness
Ultrasound or dual-energy CT	Double-contour sign, tophi or urate deposits can support disease when aspiration is difficult	Imaging findings are imperfect and do not reliably exclude an infected joint
Radiographs in established disease	Well-defined erosions with overhanging edges and preserved bone density may occur in chronic tophaceous gout	Radiographs may be normal early and are not the first test to distinguish acute infection

Differential Diagnosis

Calcium pyrophosphate deposition (CPPD) can mimic gout, often involving the knee or wrist. CPP crystals may be rhomboid or rod-shaped and have weakly positive or absent birefringence, so microscopy can miss them (Zell et al., 2021). Septic arthritis may present with identical warmth, swelling, fever and inflammatory synovial fluid, and can coexist with crystal deposits. Cellulitis, bursitis, fracture or trauma, reactive arthritis and inflammatory arthritis are additional considerations. A patient’s prior gout diagnosis should not automatically close the differential when the presentation is unusually severe, involves a prosthetic joint, follows bacteremia, or fails to respond as expected.

Diagnostic Limitations and Reassessment

A serum urate measurement obtained during a flare may need repeating once the episode resolves. During long-term urate-lowering treatment, serial levels guide dose titration, while kidney function, medication tolerance, and breakthrough flares inform follow-up (FitzGerald et al., 2020).

At the point of care

• Evaluate any first presentation or atypical hot joint for infection; aspirate when clinically indicated.
• Identify flare risk, tophi, renal function, medication interactions and frequency of attacks.
• Select acute anti-inflammatory treatment according to comorbidities rather than urate level alone.
• Plan long-term urate reduction when indicated, with a measured target and a follow-up schedule.

Management and Mechanistic Rationale

Acute flares are treated by reducing inflammation with a nonsteroidal anti-inflammatory drug (NSAID), colchicine, or a glucocorticoid, selected according to comorbidity and contraindications. Colchicine inhibits microtubule-dependent neutrophil activity; it does not dissolve urate crystals. Selected refractory or contraindicated cases may warrant IL-1-directed therapy under specialist guidance.

Urate-lowering agents act on the underlying crystal substrate. Allopurinol and febuxostat inhibit xanthine oxidase, reducing urate synthesis; uricosuric approaches increase urate excretion in selected patients. The ACR recommends a treat-to-target strategy, commonly serum urate below 6 mg/dL, with gradual titration and prophylactic anti-inflammatory therapy for at least 3–6 months when starting urate-lowering therapy (FitzGerald et al., 2020).

Do not stop established urate-lowering therapy during a flare solely because a flare has occurred. Starting it during a flare can be appropriate when indicated, with anti-inflammatory management and patient education.

Complications and Red Flags

Uncontrolled gout can progress to chronic destructive arthritis, tophi, functional limitation, and nephrolithiasis. Initial or atypical hot-joint presentations require infection evaluation. Comorbid chronic kidney disease, cardiovascular disease, and medication interactions affect anti-inflammatory choices.

Systemic illness, bacteremia risk, or a hot joint that deteriorates despite treatment requires urgent reassessment for infection, even when crystals have been identified.

Clinical Reasoning Priorities

Separate the substrate (urate supersaturation and crystal deposition) from the inflammatory flare (IL-1β and neutrophils). Long-term urate reduction prevents new crystal-related attacks; short-term anti-inflammatory drugs address symptoms and cellular activation.

A single serum urate result should not outweigh the clinical presentation and synovial fluid findings. During follow-up, however, serial urate measurements become central to confirming that treatment is reducing the crystal substrate. To organize the competing diagnoses in this presentation, use the Differential Diagnosis & Clinical Reasoning Worksheet.

Applied Clinical Reasoning

Clinical question: A 62-year-old receiving a thiazide develops sudden severe first-MTP pain overnight. Serum urate is 5.9 mg/dL. Can gout be excluded?

Reasoning: Gout remains possible despite a serum urate of 5.9 mg/dL during the flare. Consider aspiration, particularly when infection is plausible, and interpret crystals alongside microbiology. Once the flare settles, reassess urate burden, attack frequency, tophi, joint damage, and comorbidities to determine whether long-term urate lowering is indicated.

High-Yield Distinctions

Finding or scenario	Mechanistic interpretation	Clinical implication
Needle-shaped negatively birefringent crystals	Monosodium urate crystals	Support gout; assess separately for infection
Rhomboid or rod-shaped crystals with weak or absent positive birefringence	Calcium pyrophosphate deposition	Consider CPPD; identify crystals carefully because some are difficult to visualize
No arthritis despite high serum urate	Asymptomatic hyperuricemia	Do not equate urate elevation with symptomatic gout

Related YourDNP Guides

• Back to Pathophysiology
• Musculoskeletal and Rheumatic Foundations
• Immune Complex Vasculitis
• Renal Stones

---

---

References

FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello-Petersen, R., Guyatt, G., Abeles, A. M., Gelber, A. C., Harrold, L. R., Khanna, D., King, C., Levy, G., Libbey, C., Mount, D., Pillinger, M. H., Rosenthal, A., Singh, J. A., Sims, J. E., Smith, B. J., Wenger, N. S., . . . Neogi, T. (2020). 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care & Research, 72(6), 744–760. https://doi.org/10.1002/acr.24180

Gelber, A. C., Levine, S. M., & Darrah, E. (2019). Inflammatory rheumatic diseases. In G. D. Hammer & S. J. McPhee (Eds.), Pathophysiology of disease: An introduction to clinical medicine (8th ed., Chapter 24). McGraw-Hill Education. AccessMedicine

Zell, M., Aung, T., Kaldas, M., Rosenthal, A. K., Bai, B., Liu, T., Ozcan, A., & FitzGerald, J. D. (2021). Calcium pyrophosphate crystal size and characteristics. Osteoarthritis and Cartilage Open, 3(1), Article 100133. https://doi.org/10.1016/j.ocarto.2020.100133